ArticleNucleic acids research2003
Promoter choice affects the potency of HIV-1 specific RNA interference.
Article in Nucleic acids research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 107 citations in OpenAlex.
- Stable expression of shRNA for the control of recombinant adenovirus replication.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Article
- A T7 autogene-based hybrid mRNA/DNA system for long-term shRNA expression in cytoplasm without inefficient nuclear entry.Scientific reports · 2019Article
- Review
- Delineation of the Exact Transcription Termination Signal for Type 3 Polymerase III.Molecular therapy. Nucleic acids · 2018Article
- Expansion of the CRISPR-Cas9 genome targeting space through the use of H1 promoter-expressed guide RNAs.Nature communications · 2014Article
- Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.Acta naturae · 2013Article
- Illuminating the gateway of gene silencing: perspective of RNA interference technology in clinical therapeutics.Molecular biotechnology · 2012Review
- Human U6 promoter drives stronger shRNA activity than its schistosome orthologue in Schistosoma mansoni and human fibrosarcoma cells.Transgenic research · 2012Article
- The effects of stem length and core placement on shRNA activity.BMC molecular biology · 2011Article
- Regulation of U6 promoter activity by transcriptional interference in viral vector-based RNAi.Genomics, proteomics & bioinformatics · 2010Article
- Novel RNA-based strategies for therapeutic gene silencing.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- Toward a durable anti-HIV gene therapy based on RNA interference.Annals of the New York Academy of Sciences · 2009Review
- A significant increase of RNAi efficiency in human cells by the CMV enhancer with a tRNAlys promoter.Journal of biomedicine & biotechnology · 2009Article
- Applications of lentiviral vectors for shRNA delivery and transgenesis.Current gene therapy · 2008Review
- Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.Gene therapy · 2008Article
- Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Utility of Epstein-Barr virus-encoded small RNA promoters for driving the expression of fusion transcripts harboring short hairpin RNAs.Gene therapy · 2008Article
- A hybrid CMV-H1 construct improves efficiency of PEI-delivered shRNA in the mouse brain.Nucleic acids research · 2007Article
- Development of a species-specific RNA polymerase I-based shRNA expression vector.Nucleic acids research · 2007Article
- The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference.Retrovirology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference (RNAi) is mediated by small interfering (si) RNAs that target and degrade mRNA in a sequence-specific manner. Cellular expression of siRNA can be achieved by the use of expression cassettes driven by RNA polymerase III (pol III) promoters. Here, we demonstrate that a modified tRNA(met)-derived (MTD) promoter effectively drives the cellular expression of HIV-1-specific siRNA. We observed up to 56% greater inhibition of virus production when the MTD promoter was used to drive the expression of short hairpin (sh) RNA targeting the HIV-1 transactivator protein tat compared to cassettes containing other pol III promoters such as H1, U6+1 and U6+27. We conclude that the MTD promoter is ideally suited to drive intracellular expression of HIV-1 specific siRNA and may serve as an important component of future RNAi vector delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.